Sanofi, GSK to Seek Approval for Covid-19 Vaccine After Positive Trial Results
February 23 2022 - 6:09AM
Dow Jones News
By Cecilia Butini
Sanofi SA and GlaxoSmithKline PLC said Wednesday that their
jointly-developed coronavirus vaccine has shown positive results in
final-stage clinical trials and that they intend to seek regulatory
approval for the shot.
The two pharma giants said their vaccine candidate showed
efficacy against the virus when used both as primary vaccination
and as a booster dose.
Phase 3 trials of the shot showed it was 100% effective against
severe Covid-19 and hospitalization, and 75% effective against
moderate or severe disease, Sanofi and Glaxo said.
Final analysis of a booster use of the shot confirmed that it
can boost neutralizing antibodies 18- to 30-fold when used after
two doses of different available vaccines, the companies said.
Sanofi and Glaxo's Covid-19 shot was hit by development setbacks
in late 2020 but they said in December that it could deliver strong
immune response when used as a booster.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
February 23, 2022 05:54 ET (10:54 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
